TRENTON – The New Jersey Commission on Cancer Research (NJCCR) has awarded nearly $3.5 million in state Fiscal Year 2023 funding to 21 peer-reviewed cancer research grants and fellowships to support discovery-oriented cancer research. The 11-member NJCCR is the state’s only cancer commission that promotes basic, translational, fellowships and pilot cancer research grants to qualified […]
Category Archives: Cancer and neoplasms
04
Aug
Aug
Abstract Cytokines are secreted or membrane-presented molecules that mediate broad cellular functions, including development, differentiation, growth and survival. Accordingly, the regulation of cytokine activity is extraordinarily important both physiologically and pathologically. Cytokine and/or cytokine receptor engineering is being widely investigated to safely and effectively modulate cytokine activity for therapeutic benefit. IL-2 in particular has been […]
The dynamics of the pancreatic endocrine tumor market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. LAS VEGAS, Aug. 3, 2023 /PRNewswire/ — DelveInsight’s Pancreatic Endocrine Tumor Market Insights report includes a […]
03
Aug
Aug
Myelofibrosis is a disease that starts in the bone marrow, and a recent study showed that momelotinib may be beneficial to patients with the condtion. Patients with previously treated myelofibrosis (a type of myeloproliferative neoplasm) tended to benefit more regarding symptom, spleen and anemia outcomes when administered a regimen of momelotinib compared with those given […]
03
Aug
Aug
Cancer can affect all organisms, but species vary in their resistance to this disease. Due to the fact that larger body size and longer lifespan increase the likelihood of cancer, species with larger bodies and longer lifespans have evolved more robust cancer defense mechanisms. For example, the risk of dying because of cancer is 17 […]
Cancer and neoplasms
A pilot radiometabolomics integration study for the characterization of renal oncocytic neoplasia
03
Aug
Aug
Abstract Differentiating benign renal oncocytic tumors and malignant renal cell carcinoma (RCC) on imaging and histopathology is a critical problem that presents an everyday clinical challenge. This manuscript aims to demonstrate a novel methodology integrating metabolomics with radiomics features (RF) to differentiate between benign oncocytic neoplasia and malignant renal tumors. For this purpose, thirty-three renal […]
02
Aug
Aug
Investigators are also administering elraglusib in combination with a checkpoint inhibitor for those with advanced pancreatic cancer in one phase 2 study (NCT05239182) and with folinic acid, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX) for patients with metastatic pancreatic cancer in another (NCT05077800). The FDA has granted orphan drug designation to the investigational GSK-3β inhibitor elraglusib (9-ING-41) as […]
Cancer and neoplasms
Updated COVID boosters; Infant peanut exposure; AI improves breast cancer detection rate by 20%
02
Aug
Aug
doctor desk © Alena Kryazheva – stock.adobe.com Updated COVID boosters The Food and Drug Administration (FDA) could authorize Pfizer’s updated COVID boosters as early as the end of this month. The latest booster is designed to target the XBB.1.5 subvariant which has been circulating since last winter. The booster rate is low in the United […]
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million – – Announces ~20% Workforce Reduction Enhancing […]